{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:15:11Z","timestamp":1791429311787,"version":"4.3.3"},"reference-count":50,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007771","name":"Medical University of Silesia","doi-asserted-by":"publisher","award":["PCN-1-004\/K\/1\/O"],"award-info":[{"award-number":["PCN-1-004\/K\/1\/O"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007771","name":"Medical University of Silesia","doi-asserted-by":"publisher","award":["PCN-1\u2014033\/K\/0\/O"],"award-info":[{"award-number":["PCN-1\u2014033\/K\/0\/O"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Psoriasis is a chronic, recurrent, and often severe skin disease which is frequently associated with metabolic disorders and increased risk of cardiovascular complications. One of the postulated links is an intensified process of advanced protein glycation and\/or glycoxidation. Therefore, the aim of the study was to assess concentrations of N6-carboxymethyllysine (CML), N6-carboxyethyllysine (CEL), and soluble form of receptor for advanced glycation end-products (sRAGE) in psoriasis patients at different phases of the disease activity, in comparison to healthy individuals. The study material consisted of sera from psoriasis patients in active phase, in the remission phase, and healthy controls. Concentrations of CML, CEL, and sRAGE were determined using ELISA technique. In the patients with psoriasis (in both phases of the disease), concentrations of CML, CEL and sRAGE were significantly higher than in healthy individuals but they did not correlate with psoriasis area severity index (PASI) values. The remission of the disease was followed by a significant decrease in CML, CEL, and sRAGE concentrations when compared to active patients; however, these concentrations were still significantly higher than in the controls. Our data suggest that psoriasis is accompanied by an intense glycoxidation process and that high sRAGE levels seem to reflect permanent RAGE overstimulation.<\/jats:p>","DOI":"10.3390\/biom12121870","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T02:22:41Z","timestamp":1670984561000},"page":"1870","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Concentrations of N6-Carboxymethyllysine (CML), N6-Carboxyethyllysine (CEL), and Soluble Receptor for Advanced Glycation End-Products (sRAGE) Are Increased in Psoriatic Patients"],"prefix":"10.3390","volume":"12","author":[{"given":"Aleksandra","family":"Damasiewicz-Bodzek","sequence":"first","affiliation":[{"name":"Department of Chemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-9299","authenticated-orcid":false,"given":"Agnieszka","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of Myocardial Infarction in Patients With Psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2340\/00015555-0297","article-title":"Psoriasis and the Metabolic Syndrome","volume":"87","author":"Cohen","year":"2007","journal-title":"Acta Dermato-Venereologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","article-title":"Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis","volume":"298","author":"Sommer","year":"2006","journal-title":"Arch. Dermatol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: A possible risk factor for development of coronary artery calcification","volume":"156","author":"Ludwig","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1468-3083.2008.02636.x","article-title":"Psoriasis and diabetes: A population-based cross-sectional study","volume":"22","author":"Cohen","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.det.2014.09.004","article-title":"Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities","volume":"33","author":"Ryan","year":"2015","journal-title":"Dermatol. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/bjd.12490","article-title":"Quantifying cardiovascular disease risk factors in patients with psoriasis: A meta-analysis","volume":"169","author":"Miller","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcme.2015.01.005","article-title":"Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation","volume":"6","author":"Frers","year":"2015","journal-title":"IJC Metab. Endocr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/09546634.2013.860209","article-title":"Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis","volume":"26","author":"Puig","year":"2013","journal-title":"J. Dermatol. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1210\/jc.2007-1817","article-title":"The Role of Advanced Glycation End Products in Progression and Complications of Diabetes","volume":"93","author":"Goh","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","article-title":"Advanced Glycation End Products and Diabetic Complications","volume":"18","author":"Singh","year":"2014","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10719-016-9694-y","article-title":"Pathways of the Maillard reaction under physiological conditions","volume":"33","author":"Henning","year":"2016","journal-title":"Glycoconj. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3085756","DOI":"10.1155\/2019\/3085756","article-title":"Oxidative Stress and Advanced Lipoxidation and Glycation End Products (ALEs and AGEs) in Aging and Age-Related Diseases","volume":"2019","author":"Moldogazieva","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Twarda-Clapa, A., Olczak, A., Bia\u0142kowska, A.M., and Kozio\u0142kiewicz, M. (2022). Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. Cells, 11.","DOI":"10.3390\/cells11081312"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.micinf.2004.08.004","article-title":"RAGE (receptor for advanced glycation end products): A central player in the inflammatory response","volume":"6","author":"Chavakis","year":"2004","journal-title":"Microbes Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI200114002","article-title":"The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses","volume":"108","author":"Schmidt","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semcancer.2017.06.005","article-title":"An insight on the association of glycation with hepatocellular carcinoma","volume":"49","author":"Jabir","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/nu2121247","article-title":"Dietary Advanced Glycation End Products and Aging","volume":"2","year":"2010","journal-title":"Nutrients"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/ijd.IJD_396_18","article-title":"Advanced glycation end products, a potential link between psoriasis and cardiovascular disease: A case\u2013control study","volume":"64","author":"Salman","year":"2019","journal-title":"Indian J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Papagrigoraki, A., Maurelli, M., del Giglio, M., Gisondi, P., and Girolomoni, G. (2017). Advanced Glycation End Products in the Pathogenesis of Psoriasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112471"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203314559631","article-title":"Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis","volume":"24","author":"Yu","year":"2014","journal-title":"Lupus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2010","journal-title":"J. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies","volume":"70","author":"Hugh","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","first-page":"4016939","article-title":"Skin Autofluorescence, as a Measure of AGE Accumulation in Individuals Suffering from Chronic Plaque Psoriasis","volume":"2018","author":"Makulska","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1373\/clinchem.2004.031286","article-title":"Measurement of N\u03b5-(Carboxymethyl)lysine and N\u03b5-(Carboxyethyl)lysine in Human Plasma Protein by Stable-Isotope-Dilution Tandem Mass Spectrometry","volume":"50","author":"Teerlink","year":"2004","journal-title":"Clin. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00403-013-1362-5","article-title":"Serum methylglyoxal level and its association with oxidative stress and disease severity in patients with psoriasis","volume":"305","author":"Kaur","year":"2013","journal-title":"Arch. Dermatol. Res."},{"key":"ref_32","first-page":"172","article-title":"Advanced protein glycation in psoriasis","volume":"26","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1681\/ASN.2005020144","article-title":"Skin Autofluorescence, a Measure of Cumulative Metabolic Stress and Advanced Glycation End Products, Predicts Mortality in Hemodialysis Patients","volume":"16","author":"Meerwaldt","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/dia.2006.8.523","article-title":"Skin Autofluorescence, a Novel Marker for Glycemic and Oxidative Stress-Derived Advanced Glycation Endproducts: An Overview of Current Clinical Studies, Evidence, and Limitations","volume":"8","author":"Mulder","year":"2006","journal-title":"Diabetes Technol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1046\/j.1523-1747.2000.00962.x","article-title":"Increased Oxidative Damage to Fibroblasts in Skin With and Without Lesions in Psoriasis","volume":"114","author":"Gerbaud","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2340\/00015555-2661","article-title":"Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis","volume":"97","author":"Papagrigoraki","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ijd.15851","article-title":"Skin advanced glycation end products as a diagnostic and monitoring tool among psoriatic patients: How the therapy helps reduce cardiovascular disease risk","volume":"61","author":"Lanna","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Yoon, K.D., Yamamoto, K., Ueda, K., Zhou, J., and Sparrow, J.R. (2012). A Novel Source of Methylglyoxal and Glyoxal in Retina: Implications for Age-Related Macular Degeneration. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041309"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Nowak, A., Przywara-Chowaniec, B., Damasiewicz-Bodzek, A., Blachut, D., Nowalany-Kozielska, E., and Tyrpie\u0144-Golder, K. (2021). Advanced Glycation End-Products (AGEs) and Their Soluble Receptor (sRAGE) in Women Suffering from Systemic Lupus Erythematosus (SLE). Cells, 10.","DOI":"10.3390\/cells10123523"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2340\/00015555-2933","article-title":"Soluble Receptor for Advanced Glycation End Products: A Novel Biomarker for Psoriasis Severity with Therapeutic Implications?","volume":"98","author":"Baran","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"101958","DOI":"10.1016\/j.redox.2021.101958","article-title":"The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes","volume":"42","author":"Erusalimsky","year":"2021","journal-title":"Redox Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/1354750X.2020.1774654","article-title":"Plasma angiogenesis and oxidative stress markers in patients with diabetic retinopathy","volume":"25","author":"Gaonkar","year":"2020","journal-title":"Biomarkers"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.freeradbiomed.2007.03.015","article-title":"Soluble RAGE in type 2 diabetes: Association with oxidative stress","volume":"43","author":"Devangelio","year":"2007","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.freeradbiomed.2007.06.017","article-title":"Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins","volume":"43","author":"Santilli","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0035-1570754","article-title":"Atherosclerosis and the Hypercholesterolemic AGE\u2013RAGE Axis","volume":"25","author":"Qureshi","year":"2016","journal-title":"Int. J. Angiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fendo.2019.00426","article-title":"Could AGE\/RAGE-Related Oxidative Homeostasis Dysregulation Enhance Susceptibility to Pathogenesis of Cardio-Metabolic Complications in Childhood Obesity?","volume":"10","author":"Corica","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jdiacomp.2014.12.007","article-title":"Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients","volume":"29","author":"Huang","year":"2015","journal-title":"J. Diabetes its Complicat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.dsx.2020.07.036","article-title":"Action of metformin therapy against advanced glycation, oxidative stress and inflammation in type 2 diabetes patients: 3 months follow-up study","volume":"14","author":"Adeshara","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.atherosclerosis.2013.01.016","article-title":"Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes","volume":"227","author":"Fujisawa","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2017.08.015","article-title":"Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease","volume":"266","author":"Reichert","year":"2017","journal-title":"Atherosclerosis"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/12\/1870\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:40:39Z","timestamp":1760146839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/12\/1870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["biom12121870"],"URL":"https:\/\/doi.org\/10.3390\/biom12121870","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]}}}